ArticleCancer management and research2026
Six-Transmembrane Epithelial Antigen of the Prostate 1 Promotes HCC Proliferation and Metastasis in vitro and in vivo via the Wnt/β-Catenin Signaling Pathway.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the role and underlying mechanism of Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) in Hepatocellular carcinoma (HCC) progression, and to validate its potential as a therapeutic target. Materials and Methods: In this study, STEAP1-knockdown models were used to evaluate cell proliferation, invasion and migration. RNA sequencing (RNA-seq) were performed to explore downstream mechanisms. Subcutaneous Xenograft Model in nude mice was used to investigate the role of STEAP1 in the proliferation of HCC in vivo. Results: STEAP1 knockdown significantly inhibited HCC cell proliferation, invasion, and migration, downregulated the expression of EMT-related proteins, and suppressed activation of the Wnt signaling pathway. In vivo, STEAP1 silencing effectively reduced the growth of subcutaneous tumors in nude mice. Conclusion: STEAP1 promotes HCC growth and metastasis by activating the Wnt/β-catenin signaling pathway, and may serve as a promising therapeutic target for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.